11.73
-0.01(-0.09%)
Currency In USD
| Previous Close | 11.74 |
| Open | 11.8 |
| Day High | 12.24 |
| Day Low | 11.5 |
| 52-Week High | 26.56 |
| 52-Week Low | 5.66 |
| Volume | 139,675 |
| Average Volume | 121,282 |
| Market Cap | 193.99M |
| PE | -0.79 |
| EPS | -14.8 |
| Moving Average 50 Days | 9.75 |
| Moving Average 200 Days | 9.69 |
| Change | -0.01 |
If you invested $1000 in RAPT Therapeutics, Inc. (RAPT) since IPO date, it would be worth $112.79 as of August 18, 2025 at a share price of $11.73. Whereas If you bought $1000 worth of RAPT Therapeutics, Inc. (RAPT) shares 5 years ago, it would be worth $60.59 as of August 18, 2025 at a share price of $11.73.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
RAPT Therapeutics Names Two Industry Veterans to its Board of Directors
GlobeNewswire Inc.
Jun 23, 2025 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients l
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
GlobeNewswire Inc.
Jun 13, 2025 1:00 PM GMT
SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapie
RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development
GlobeNewswire Inc.
Apr 15, 2025 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients